Table Info

Table 1.

Randomized trials of tamoxifen vs. AIs in the adjuvant breast cancer setting

Clinical trial comparison(s)	N. of cases(menopausal status)	Follow (years)up	Overall results	Predictive effects by BMI	References
ATAC A vs. T	4,939 (post)	8.3	A better than T	A better than T at all BMI levels A less effective when BMI ≥ 30 for DDFS A relative benefit of A vs. T when BMI low	[7]
TEAM E vs. T → E	4,700 (post)	5.1	E = T 95% CI (0.39–0.84)	E better than T (2.75 years) at all BMI levels, significant in BMI > 30 (DDFS HR = 0.57, 95% CI = 0.39–0.84) E better than T → E (5.1 years) for any BMI (ns), BMI > 30 (DDFS HR = 0.75, 95% CI = 0.56–1.01 and OS HR = 0.71, 95% CI = 0.51–1.01)	[10]
ABCSG-12 A + G vs. T + G	1,684 (pre)	5.2	A + G = T + G (DFS) A + G worse than T + G (OS)	BMI < 25: A = T (DFS, OS) BMI ≥ 25: A worse than T HR = 1.49, 95% CI = 0.93–2.03 (DFS) HR = 3.03, 95% CI = 1.35–6.82 (OS)	[8]
BIG 1–98 L vs. T vs. L → T vs. T → L	4,760 (post)	8.7	L better than T (DFS, DDFS, OS) L → T or T → L = L	Treatment by BMI interactions (ns) L vs. T HR: 0.77 NW, 0.68 OW, 0.78 OB	[11]

N.: number of cases; A: anastrozole; T: tamoxifen; L: letrozole; E: exemestane; G: goserelin; T → E: tamoxifen followed by exemestane; L → T: letrozole followed by tamoxifen; T → L: tamoxifen followed by letrozole; BIG 1–98: breast international group 1–98 trial; NW: normal weight; OW: overweight; OB: obese; DDFS: distant disease-free survival; DFS: disease-free survival; OS: overall survival; ns: not significant

Declarations

Author contributions

The author contributed solely to the work.

Conflicts of interest

The author declares no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

Not applicable.

Copyright

References

Janssen I, Powell LH, Jasielec MS, Kazlauskaite R. Covariation of change in bioavailable testosterone and adiposity in midlife women. Obesity. 2015;23:488–94. [DOI] [PubMed] [PMC]

Janssen I, Powell LH, Kazlauskaite R, Dugan SA. Testosterone and visceral fat in midlife women: the study of women’s health across the nation (SWAN) fat patterning study. Obesity. 2010;18:604–10. [DOI] [PubMed] [PMC]

Wang X, Simpson ER, Brown KA. Aromatase overexpression in dysfunctional adipose tissue links obesity to postmenopausal breast cancer. J Steroid Biochem Mol Biol. 2015;153:35–44. [DOI] [PubMed]

Warner M, Gustafsson JA. On estrogen, cholesterol metabolism, and breast cancer. N Engl J Med. 2014;370:572–3. [DOI] [PubMed]

Wei W, Schwaid AG, Wang X, Wang X, Chen S, Chu Q, et al. Ligand activation of ERRα by cholesterol mediates statin and bisphosphonate effects. Cell Metab. 2016;23:479–91. [DOI] [PubMed] [PMC]

Chang M. Tamoxifen resistance in breast cancer. Biomol Ther. 2012;20:256–67. [DOI] [PubMed] [PMC]

Sestak I, Distler W, Forbes JF, Dowsett M, Howell A, Cuzick J. Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial. J Clin Oncol. 2010;28:3411–5. [DOI] [PubMed]

Pfeiler G, Königsberg R, Fesl C, Mlineritsch B, Stoeger H, Singer CF, et al. Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trial. J Clin Oncol. 2011;29:2653–9. [DOI] [PubMed]

Wolters R, Schwentner L, Regierer A, Wischnewsky M, Kreienberg R, Wöckel A. Endocrine therapy in obese patients with primary breast cancer: another piece of evidence in an unfinished puzzle. Breast Cancer Res Treat. 2012;131:925–31. [DOI] [PubMed]

10.

Seynaeve C, Hille E, Hasenburg A, Rea D, Markopoulos C, Hozumi Y, et al. The impact of body mass index (BMI) on the efficacy of adjuvant endocrine therapy in postmenopausal hormone sensitive breast cancer (BC) patients; exploratory analysis from the TEAM study. Cancer Res. 2010;70:S2–3. [DOI]

11.

Ewertz M, Gray KP, Regan MM, Ejlertsen B, Price KN, Thürlimann B, et al. Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trial. J Clin Oncol. 2012;30:3967–75. [DOI] [PubMed] [PMC]

12.

Marchais-Oberwinkler S, Henn C, Möller G, Klein T, Negri M, Oster A, et al. 17β-Hydroxysteroid dehydrogenases (17β-HSDs) as therapeutic targets: protein structures, functions, and recent progress in inhibitor development. J Steroid Biochem Mol Biol. 2011;125:66–82. [DOI] [PubMed]

13.

Starčević Š, Turk S, Brus B, Cesar J, Lanišnik Rižner T, Gobec S. Discovery of highly potent, nonsteroidal 17β-hydroxysteroid dehydrogenase type 1 inhibitors by virtual high-throughput screening. J Steroid Biochem Mol Biol. 2011;127:255–61. [DOI] [PubMed]

14.

Saloniemi T, Järvensivu P, Koskimies P, Jokela H, Lamminen T, Ghaem-Maghami S, et al. Novel hydroxysteroid (17β) dehydrogenase 1 inhibitors reverse estrogen-induced endometrial hyperplasia in transgenic mice. Am J Pathol. 2010;176:1443–51. [DOI] [PubMed] [PMC]

15.

Ayan D, Maltais R, Roy J, Poirier D. A new nonestrogenic steroidal inhibitor of 17β-hydroxysteroid dehydrogenase type I blocks the estrogen-dependent breast cancer tumor growth induced by estrone. Mol Cancer Ther. 2012;11:2096–104. [DOI] [PubMed]

16.

Poirier D, Roy J, Maltais R. A targeted-covalent inhibitor of 17β-HSD1 blocks two estrogen-biosynthesis pathways: in vitro (metabolism) and in vivo (xenograft) studies in T-47D breast cancer models. Cancers. 2021;13:1841. [DOI] [PubMed] [PMC]

17.

Sadozai H. Steroid sulfatase inhibitors: promising new therapy for breast cancer. J Pak Med Assoc. 2013;63:509–15. [PubMed]

18.

Stanway SJ, Delavault P, Purohit A, Woo LW, Thurieau C, Potter BV, et al. Steroid sulfatase: a new target for the endocrine therapy of breast cancer. Oncologist. 2007;12:370–4. [DOI] [PubMed]

19.

Sang X, Han H, Poirier D, Lin SX. Steroid sulfatase inhibition success and limitation in breast cancer clinical assays: an underlying mechanism. J Steroid Biochem Mol Biol. 2018;183:80–93. [DOI] [PubMed]

20.

Lespérance M, Roy J, Djiemeny Ngueta A, Maltais R, Poirier D. Synthesis of 16β-derivatives of 3-(2-bromoethyl)-estra-1,3,5(10)-trien-17β-ol as inhibitors of 17β-HSD1 and/or steroid sulfatase for the treatment of estrogen-dependent diseases. Steroids. 2021;172:108856. [DOI] [PubMed]

21.

Salah M, Abdelsamie AS, Frotscher M. First dual inhibitors of steroid sulfatase (STS) and 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1): designed multiple ligands as novel potential therapeutics for estrogen-dependent diseases. J Med Chem. 2017;60:4086–92. [DOI] [PubMed]

22.

Woo LW, Wood PM, Bubert C, Thomas MP, Purohit A, Potter BV. Synthesis and structure–activity relationship studies of derivatives of the dual aromatase–sulfatase inhibitor 4-{[(4-cyanophenyl)(4H-1,2,4-triazol-4-yl) amino]methyl}phenyl sulfamate. Chem Med Chem. 2013;8:779–99. [DOI] [PubMed] [PMC]

23.

Bubert C, Woo LW, Sutcliffe OB, Mahon MF, Chander SK, Purohit A, et al. Synthesis of aromatase inhibitors and dual aromatase steroid sulfatase inhibitors by linking an arylsulfamate motif to 4-(4H-1,2,4-triazol-4-ylamino)benzonitrile: SAR, crystal structures, in vitro and in vivo activities. Chem Med Chem. 2008;3:1708–30. [DOI] [PubMed]

24.

Iannelli F, Lombardi R, Milone MR, Pucci B, De Rienzo S, Budillon A, et al. Targeting mevalonate pathway in cancer treatment: repurposing of statins. Recent Pat Anticancer Drug Discov. 2018;13:184–200. [DOI] [PubMed]

25.

Zhang FL, Casey PJ. Protein prenylation: molecular mechanisms and functional consequences. Annu Rev Biochem. 1996;65:241–69. [DOI] [PubMed]

26.

Seabra MC. Membrane association and targeting of prenylated Ras-like GTPases. Cell Signal. 1998;10:167–72. [DOI] [PubMed]

27.

Xue L, Qi H, Zhang H, Ding L, Huang Q, Zhao D, et al. Targeting SREBP-2-regulated mevalonate metabolism for cancer therapy. Front Oncol. 2020;10:1510. [DOI] [PubMed] [PMC]

28.

Griffiths B, Lewis CA, Bensaad K, Ros S, Zhang Q, Ferber EC, et al. Sterol regulatory element binding protein-dependent regulation of lipid synthesis supports cell survival and tumor growth. Cancer Metab. 2013;1:3. [DOI] [PubMed] [PMC]

29.

Stein EA, Bays H, O’Brien D, Pedicano J, Piper E, Spezzi A. Lapaquistat acetate: development of a squalene synthase inhibitor for the treatment of hypercholesterolemia. Circulation. 2011;123:1974–85. [DOI] [PubMed]

30.

Belter A, Skupinska M, Giel-Pietraszuk M, Grabarkiewicz T, Rychlewski L, Barciszewski J. Squalene monooxygenase - a target for hypercholesterolemic therapy. Biol Chem. 2011;392:1053–75. [DOI] [PubMed]

31.

Hidaka Y, Hotta H, Nagata Y, Iwasawa Y, Horie M, Kamei T. Effect of a novel squalene epoxidase inhibitor, NB-598, on the regulation of cholesterol metabolism in Hep G2 cells. J Biol Chem. 1991;266:13171–7. [DOI] [PubMed]

32.

Maione F, Oliaro-Bosso S, Meda C, Di Nicolantonio F, Bussolino F, Balliano G, et al. The cholesterol biosynthesis enzyme oxidosqualene cyclase is a new target to impair tumour angiogenesis and metastasis dissemination. Sci Rep. 2015;5:9054. [DOI] [PubMed] [PMC]

33.

Liang Y, Besch-Williford C, Aebi JD, Mafuvadze B, Cook MT, Zou X, et al. Cholesterol biosynthesis inhibitors as potent novel anti-cancer agents: suppression of hormone-dependent breast cancer by the oxidosqualene cyclase inhibitor RO 48-8071. Breast Cancer Res Treat. 2014;146:51–62. [DOI] [PubMed]

34.

Corcos L, Le Jossic-Corcos C. Statins: perspectives in cancer therapeutics. Dig Liver Dis. 2013;45:795–802. [DOI] [PubMed]

35.

Nam GH, Kwon M, Jung H, Ko E, Kim SA, Choi Y, et al. Statin-mediated inhibition of RAS prenylation activates ER stress to enhance the immunogenicity of KRAS mutant cancer. J Immunother Cancer. 2021;9:e002474. [DOI] [PubMed] [PMC]

36.

Manthravadi S, Shrestha A, Madhusudhana S. Impact of statin use on cancer recurrence and mortality in breast cancer: a systematic review and meta-analysis. Int J Cancer. 2016;139:1281–8. [DOI] [PubMed]

37.

Harborg S, Heide-Jørgensen U, Ahern TP, Ewertz M, Cronin-Fenton D, Borgquist S. Statin use and breast cancer recurrence in postmenopausal women treated with adjuvant aromatase inhibitors: a Danish population-based cohort study. Breast Cancer Res Treat. 2020;183:153–60. [DOI] [PubMed] [PMC]

38.

Nowakowska MK, Lei X, Thompson MT, Shaitelman SF, Wehner MR, Woodward WA, et al. Association of statin use with clinical outcomes in patients with triple-negative breast cancer. Cancer. 2021;127:4142–50. [DOI] [PubMed]

39.

Langballe R, Cronin-Fenton D, Dehlendorff C, Jensen MB, Ejlertsen B, Andersson M, et al. Statin use and risk of contralateral breast cancer: a nationwide cohort study. Br J Cancer. 2018;119:1297–305. [DOI] [PubMed] [PMC]

40.

Liu B, Yi Z, Guan X, Zeng YX, Ma F. The relationship between statins and breast cancer prognosis varies by statin type and exposure time: a meta-analysis. Breast Cancer Res Treat. 2017;164:1–11. [DOI] [PubMed]

41.

Goard CA, Chan-Seng-Yue M, Mullen PJ, Quiroga AD, Wasylishen AR, Clendening JW, et al. Identifying molecular features that distinguish fluvastatin-sensitive breast tumor cells. Breast Cancer Res Treat. 2014;143:301–12. [DOI] [PubMed]

42.

Kimbung S, Lettiero B, Feldt M, Bosch A, Borgquist S. High expression of cholesterol biosynthesis genes is associated with resistance to statin treatment and inferior survival in breast cancer. Oncotarget. 2016;7:59640–51. [DOI] [PubMed] [PMC]

43.

Göbel A, Breining D, Rauner M, Hofbauer LC, Rachner TD. Induction of 3-hydroxy-3-methylglutaryl-CoA reductase mediates statin resistance in breast cancer cells. Cell Death Dis. 2019;10:91. [DOI] [PubMed] [PMC]

44.

Feldt M, Menard J, Rosendahl AH, Lettiero B, Bendahl PO, Belting M, et al. The effect of statin treatment on intratumoral cholesterol levels and LDL receptor expression: a window-of-opportunity breast cancer trial. Cancer Metab. 2020;8:25. [DOI] [PubMed] [PMC]

45.

Choi Y, Kawazoe Y, Murakami K, Misawa H, Uesugi M. Identification of bioactive molecules by adipogenesis profiling of organic compounds. J Biol Chem. 2003;278:7320–4. [DOI] [PubMed]

46.

Kamisuki S, Mao Q, Abu-Elheiga L, Gu Z, Kugimiya A, Kwon Y, et al. A small molecule that blocks fat synthesis by inhibiting the activation of SREBP. Chem Biol. 2009;16:882–92. [DOI] [PubMed]

47.

Brovkovych V, Izhar Y, Danes JM, Dubrovskyi O, Sakallioglu IT, Morrow LM, et al. Fatostatin induces pro- and anti-apoptotic lipid accumulation in breast cancer. Oncogenesis. 2018;7:66. [DOI] [PubMed] [PMC]

48.

Chlebowski RT, McTiernan A, Wactawski-Wende J, Manson JE, Aragaki AK, Rohan T, et al. Diabetes, metformin, and breast cancer in postmenopausal women. J Clin Oncol. 2012;30:2844–52. [DOI] [PubMed] [PMC]

49.

Tapia E, Villa-Guillen DE, Chalasani P, Centuori S, Roe DJ, Guillen-Rodriguez J, et al. A randomized controlled trial of metformin in women with components of metabolic syndrome: intervention feasibility and effects on adiposity and breast density. Breast Cancer Res Treat. 2021;190:69–78. [DOI] [PubMed] [PMC]

50.

DeCensi A, Puntoni M, Goodwin P, Cazzaniga M, Gennari A, Bonanni B, et al. Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res. 2010;3:1451–61. [DOI] [PubMed]

51.

Ko KP, Ma SH, Yang JJ, Hwang Y, Ahn C, Cho YM, et al. Metformin intervention in obese non-diabetic patients with breast cancer: phase II randomized, double-blind, placebo-controlled trial. Breast Cancer Res Treat. 2015;153:361–70. [DOI] [PubMed]

52.

Madiraju AK, Erion DM, Rahimi Y, Zhang XM, Braddock DT, Albright RA, et al. Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. Nature. 2014;510:542–6. [DOI] [PubMed] [PMC]

53.

Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest. 2001;108:1167–74. [DOI] [PubMed] [PMC]

54.

Lei Y, Yi Y, Liu Y, Liu X, Keller ET, Qian CN, et al. Metformin targets multiple signaling pathways in cancer. Chin J Cancer. 2017;36:17. [DOI] [PubMed] [PMC]

55.

Sharma A, Bandyopadhayaya S, Chowdhury K, Sharma T, Maheshwari R, Das A, et al. Metformin exhibited anticancer activity by lowering cellular cholesterol content in breast cancer cells. PLoS One. 2019;14:e0209435. [DOI] [PubMed] [PMC]

56.

Liu S, Jing F, Yu C, Gao L, Qin Y, Zhao J. AICAR-induced activation of AMPK inhibits TSH/SREBP-2/HMGCR pathway in liver. PLoS One. 2015;10:e0124951. [DOI] [PubMed] [PMC]

57.

Zhang F, Sun W, Chen J, Jiang L, Yang P, Huang Y, et al. SREBP-2, a new target of metformin? Drug Des Devel Ther. 2018;12:4163–70. [DOI] [PubMed] [PMC]

58.

Brown KA. Impact of obesity on mammary gland inflammation and local estrogen production. J Mammary Gland Biol Neoplasia. 2014;19:183–9. [DOI] [PubMed]

59.

Morris PG, Hudis CA, Giri D, Morrow M, Falcone DJ, Zhou XK, et al. Inflammation and increased aromatase expression occur in the breast tissue of obese women with breast cancer. Cancer Prev Res. 2011;4:1021–9. [DOI] [PubMed] [PMC]

60.

Lee Argov EJ, Acheampong T, Terry MB, Rodriguez CB, Agovino M, Wei Y, et al. Independent and joint cross-sectional associations of statin and metformin use with mammographic breast density. Breast Cancer Res. 2020;22:99. [DOI] [PubMed] [PMC]